




RealRate

PHARMACEUTICAL 2022

Homology Medicines Inc.
Rank 278 of 475

HOMOLOGY
Medicines, Inc.



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2022

Homology Medicines Inc.
Rank 278 of 475



The relative strengths and weaknesses of Homology Medicines Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Homology Medicines Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 39% points. The greatest weakness of Homology Medicines Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -159%, being 117% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	191,909
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,226
Liabilities, Non-Current	24,844
Other Assets	17,560
Other Compr. Net Income	-7.0
Other Expenses	0
Other Liabilities	0
Other Net Income	185
Property and Equipment	2,252
Research and Development	93,085
Revenues	33,971
Selling, General and Administrative Expense	36,835

Output Variable	Value in 1000 USD
Assets	211,721
Liabilities	42,070
Expenses	129,920
Stockholders Equity	169,651
Net Income	-95,764
Comprehensive Net Income	-95,768
Economic Capital Ratio	-159%

